KAMURA
Orforglipron
Orforglipron (Oral GLP-1 Receptor Agonist)
Investigational oral GLP-1 receptor agonist by Eli Lilly. Unlike injectable GLP-1s, orforglipron is a small molecule taken as a daily pill. Phase 3 trials show significant weight loss and metabolic improvements comparable to injectable alternatives.
📊 Evidence by Outcome
Significant weight loss
3 studies • Consistency: Moderate • Effect: Moderate
Improved glycemic control
3 studies • Consistency: Moderate • Effect: Moderate
Reduced appetite
3 studies • Consistency: Moderate • Effect: Moderate
No injection needed
3 studies • Consistency: Moderate • Effect: Moderate
Key Research
Peer-Reviewed Evidence • 1 Citations
Orforglipron Phase 2 Trial (ATTAIN)
••2023
Key Finding: Up to 14.7% body weight reduction at 36 weeks with the highest dose, comparable to injectable GLP-1 RAs
Citations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
TBD (not yet approved)
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Where to Get It (UAE)
Browse all wellness centers →Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.